In RAE Cho
Seoul National University · 医学
研究室紹介
Professor In RAE Cho's research lab specializes in gastrointestinal and hepatobiliary diseases, with a strong focus on pancreatic disorders, liver cancer, and the role of inflammatory markers in disease progression. The lab investigates clinical outcomes, treatment efficacy, and prognostic factors in conditions such as acute pancreatitis, cholangiocarcinoma, and hepatocellular carcinoma, particularly in the context of diabetes and comorbidities. Using large-scale population-based data and advanced endoscopic techniques like EUS-guided drainage, the lab aims to improve early diagnosis and personalized treatment strategies. Their work emphasizes translational research that bridges biomarkers, clinical outcomes, and health economics.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Treatment efficacy and economic burdens were comparable between the two regimens. But, the details of adverse event were different. Gem + nabPTX regimen might be considered preferentially in certain conditions.
IL-6, CRP2, and CTSI are helpful for early differentiation of AP severity. Among inflammatory markers, IL-6 has the advantage of early prediction of mild pancreatitis at the time of admission.
Treatment outcomes of EUS-guided drainage using a novel LAMS were feasible despite the significantly high proportion of WON. The LAMS allowed acceptable treatment outcomes for EUS-guided drainage.
BACKGROUND: Although diabetes is reportedly associated with the occurrence of acute pancreatitis (AP), the risk of AP according to the duration and severity of diabetes is not yet clear. We aimed to investigate the risk of AP based on glycemic status and the presence of comorbidities using a nationwide population-based study. METHODS: We enrolled 3,912,496 adults who underwent health examinations under the National Health Insurance Service in 2009. All participants were categorized by glycemic s
Conditional survival (CS) provides a prognosis of patients who have already survived several years after treatment. We investigated CS in Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) with or without concurrent radiotherapy (CRT). A total of 181 patients diagnosed with HCC who were treated with HAIC with or without CRT between 2011 and 2015 were retrospectively reviewed. Overall survival (OS) and
Cholangiocarcinoma (CCA), especially intrahepatic CCA, is known to share several risk factors with hepatocellular carcinoma (HCC) and liver cirrhosis has been proposed as a common pathogenic factor. We aimed to identify the risk factors of CCA and to examine differences in risk factors between CCA and HCC. We followed 510,217 Korean adults who underwent health checkups during 2002−2003 until 2013 via linkage to national hospital discharge records. Hazard ratios (HRs) were calculated after adjust
You have accessJournal of UrologyModerated Poster, Saturday, May 21, 2005, 3:30 - 5:30 pm1 Apr 2005101: Clinical Outcome of Acute Prostatitis, a Multicenter Study In Rae Cho, K.S. Lee, J.S. Jeon, S.S. Park, L.C. Sung, Choong Hee Noh, Won Jae Yang, Young Deuk Choi, S.J. Hong, Seung Choul Yang, Jin Seon Cho, H.S. Ahn, Se Joong Kim, Hong Sup Kim, K. Song, D.H. Seong, Jun Kyu Suh, K.S. Lee, Dong H. Lee, Yun Seob Song, and Y.S. Kim In Rae ChoIn Rae Cho More articles by this author , K.S. LeeK.S. Lee